Platform trials - Sorbonne Université Access content directly
Journal Articles Therapies Year : 2023

Platform trials

Olivier Demarcq
  • Function : Author
Cécile Fouret
  • Function : Author
Charlotte Gourio
  • Function : Author
Aurélie Guérin
  • Function : Author


For the past few years, platform trials have experienced a significant increase, recently amplified by the COVID-19 pandemic. The implementation of a platform trial is par-ticularly useful in certain pathologies, particularly when there is a significant number of drug candidates to be assessed, a rapid evolution of the standard of care or in situations of urgent need for evaluation, during which the pooling of protocols and infrastructure optimizes the number of patients to be enrolled, the costs, and the deadlines for carrying out the investiga-tion. However, the specificity of platform trials raises methodological, ethical, and regulatory issues, which have been the subject of the round table and which are presented in this article. The round table was also an opportunity to discuss the complexity of sponsorship and data management related to the multiplicity of partners, funding, and governance of these trials, and the level of acceptability of their findings by the competent authorities.
Fichier principal
Vignette du fichier
1-s2.0-S0040595722002773-am.pdf (656.8 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04249795 , version 1 (23-02-2024)



Matthieu Roustit, Olivier Demarcq, Silvy Laporte, Philippe Barthélémy, Olivier Chassany, et al.. Platform trials. Therapies, 2023, 78 (1), pp.29-38. ⟨10.1016/j.therap.2022.12.003⟩. ⟨hal-04249795⟩
41 View
1 Download



Gmail Facebook X LinkedIn More